OLMA

+ Watchlist + Portfolio

Olema Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $11.31
52-Week Range: $5.35 – $36.26
Market Cap: $953.72M
P/E (TTM): —
EPS (TTM): -2.12
Dividend Yield: —

Advanced Metrics

Price/Book: 2.21
PEG Ratio: —
Return on Equity: -52.74%
Return on Assets: -31.82%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 8.86
Debt/Equity: 0.01
Total Debt: $3.66M
Free Cash Flow: $-89.06M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $532.19M

OLMA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$82.27M	$86.14M	$124.52M	$157.70M
Selling, General & Admin	$24.71M	$18.82M	$17.74M	$21.00M
Operating Expenses	$106.99M	$104.96M	$142.26M	$178.70M
Operating Income	-$106.99M	-$104.96M	-$142.26M	-$178.70M
EBITDA	-$106.63M	-$104.58M	-$141.87M	-$178.21M
Pretax Income	-$104.79M	-$96.66M	-$129.47M	-$162.45M
Net Income	-$104.79M	-$96.66M	-$129.47M	-$162.45M
Diluted EPS	-2.62	-2.14	-2.20	-1.87
Diluted Shares	40.00M	45.25M	58.74M	87.01M

OLMA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$23.70M	$68.54M	$139.48M	$48.30M
Receivables	$319.00K	$673.00K	$2.12M	$4.06M
Current Assets	$208.90M	$266.51M	$438.47M	$515.45M
Total Assets	$215.65M	$276.94M	$450.98M	$533.43M
Current Liabilities	$16.55M	$21.62M	$41.76M	$51.80M
Long-Term Debt	—	—	—	$3.00M
Total Debt	$2.56M	$2.42M	$1.43M	$4.19M
Total Liabilities	$18.10M	$23.05M	$42.02M	$54.87M
Retained Earnings	-$208.98M	-$305.63M	-$435.11M	-$597.56M
Shareholders' Equity	$197.55M	$253.90M	$408.96M	$478.56M
Working Capital	$192.35M	$244.89M	$396.71M	$463.65M

OLMA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$82.06M	-$83.73M	-$104.35M	-$146.72M
Capital Expenditure	-$363.00K	—	-$159.00K	—
Free Cash Flow	-$82.43M	-$83.73M	-$104.51M	-$146.72M
Depreciation & Amortisation	$357.00K	$377.00K	$393.00K	$490.00K
Stock-Based Compensation	$18.83M	$17.26M	$22.58M	$17.59M
Investing Cash Flow	$91.48M	-$4.85M	-$93.53M	-$155.76M
Financing Cash Flow	$476.00K	$133.41M	$268.82M	$211.30M
Net Change in Cash	$9.89M	$44.84M	$70.94M	-$91.18M

OLMA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$30.62M	$43.90M	$39.95M	$43.22M	$49.23M
Selling, General & Admin	$4.25M	$3.96M	$5.93M	$6.86M	$8.75M
Operating Expenses	$34.87M	$47.86M	$45.88M	$50.08M	$57.99M
Operating Income	-$34.87M	-$47.86M	-$45.88M	-$50.08M	-$57.99M
EBITDA	-$34.74M	-$47.73M	-$45.83M	-$49.90M	-$57.87M
Pretax Income	-$30.39M	-$43.78M	-$42.22M	-$46.06M	-$53.09M
Net Income	-$30.39M	-$43.78M	-$42.22M	-$46.06M	-$53.09M
Diluted EPS	-0.36	-0.51	-0.49	—	-0.52
Diluted Shares	85.43M	85.50M	85.73M	—	102.80M

OLMA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$50.64M	$52.47M	$35.26M	$48.30M	$52.55M
Receivables	$1.92M	$2.75M	$2.97M	$4.06M	$3.35M
Current Assets	$396.66M	$367.73M	$334.33M	$515.45M	$513.23M
Total Assets	$409.64M	$382.00M	$352.45M	$533.43M	$530.64M
Current Liabilities	$26.06M	$33.16M	$41.66M	$51.80M	$47.17M
Long-Term Debt	—	$3.00M	$3.00M	$3.00M	$3.00M
Total Debt	$1.15M	$4.75M	$4.48M	$4.19M	$3.96M
Total Liabilities	$26.19M	$36.77M	$44.97M	$54.87M	$50.17M
Retained Earnings	-$465.50M	-$509.28M	-$551.50M	-$597.56M	-$650.65M
Shareholders' Equity	$383.45M	$345.24M	$307.49M	$478.56M	$480.48M
Working Capital	$370.60M	$334.56M	$292.67M	$463.65M	$466.06M

OLMA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$43.98M	-$29.88M	-$34.53M	-$38.33M	-$45.99M
Free Cash Flow	-$43.98M	-$29.88M	-$34.53M	-$38.33M	-$45.99M
Depreciation & Amortisation	$128.00K	$132.00K	$43.00K	$187.00K	$119.00K
Stock-Based Compensation	$4.38M	$4.69M	$4.25M	$4.27M	$10.15M
Investing Cash Flow	-$45.08M	$34.23M	$17.27M	-$162.18M	$4.53M
Financing Cash Flow	$222.00K	-$2.52M	$41.00K	$213.55M	$45.70M
Net Change in Cash	-$88.84M	$1.83M	-$17.21M	$13.04M	$4.25M

Market Snapshot

About

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for estrogen receptor-positive breast cancer. The company focuses on endocrine therapies designed to overcome resistance mechanisms in HR+ breast cancer. Olema's lead candidate is palazestrant, a complete estrogen receptor antagonist in clinical trials.